Skip to Content
Merck
CN
  • The effect of methotrexate injection for treatment of an ectopic pregnancy on ovarian reserve.

The effect of methotrexate injection for treatment of an ectopic pregnancy on ovarian reserve.

Fertility and sterility (2014-02-19)
ChengWei Xiao, Michael H Dahan
PMID24534282
MATERIALS
Product Number
Brand
Product Description
Y0001668
Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard
M7824
SAFC
Methotrexate
M8407
Sigma-Aldrich
Methotrexate hydrate, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
A6770
Sigma-Aldrich
Methotrexate hydrate, ≥98% (HPLC), powder
M-136
Supelco
Methotrexate solution, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
M1000000
Methotrexate, European Pharmacopoeia (EP) Reference Standard
Y0000602
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
M9929
Sigma-Aldrich
Methotrexate, meets USP testing specifications
06563
Sigma-Aldrich
Methotrexate hydrate, ≥99.0% (sum of enantiomers, HPLC)
PHR1396
Supelco
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material